ARGENX SE(EBR:ARGX) stock Fundamental Analysis

Fundamental Rating

Overall ARGX gets a fundamental rating of 5 out of 10. We evaluated ARGX against 72 industry peers in the Biotechnology industry. ARGX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ARGX is valued quite expensive, but it does show an excellent growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year ARGX was profitable.

ARGX had negative earnings in 4 of the past 5 years.

ARGX had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

ARGX's Return On Assets of 17.37% is amongst the best of the industry. ARGX outperforms 100.00% of its industry peers.

Looking at the Return On Equity, with a value of 19.54%, ARGX belongs to the top of the industry, outperforming 91.67% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	17.37%
ROE	19.54%
ROIC	N/A

ROA(3y)N/A

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

ARGX has a better Profit Margin (38.03%) than 97.22% of its industry peers.

Looking at the Gross Margin, with a value of 89.62%, ARGX belongs to the top of the industry, outperforming 87.50% of the companies in the same industry.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	38.03%
GM	89.62%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ARGX does not have a ROIC to compare to the WACC, probably because it is not profitable.

ARGX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

An Altman-Z score of 42.06 indicates that ARGX is not in any danger for bankruptcy at the moment.

ARGX's Altman-Z score of 42.06 is amongst the best of the industry. ARGX outperforms 98.61% of its industry peers.

A Debt/Equity ratio of 0.01 indicates that ARGX is not too dependend on debt financing.

ARGX has a Debt to Equity ratio of 0.01. This is amongst the best in the industry. ARGX outperforms 87.50% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.01
Debt/FCF	N/A
Altman-Z	42.06

ROIC/WACCN/A

WACC7.37%

2.3 Liquidity

ARGX has a Current Ratio of 8.53. This indicates that ARGX is financially healthy and has no problem in meeting its short term obligations.

ARGX's Current ratio of 8.53 is amongst the best of the industry. ARGX outperforms 94.44% of its industry peers.

A Quick Ratio of 7.88 indicates that ARGX has no problem at all paying its short term obligations.

ARGX has a better Quick ratio (7.88) than 93.06% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	8.53
Quick Ratio	7.88

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

ARGX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 146.30%, which is quite impressive.

Looking at the last year, ARGX shows a very strong growth in Revenue. The Revenue has grown by 23.38%.

ARGX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 94.61% yearly.

EPS 1Y (TTM)146.3%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%194.05%

Revenue 1Y (TTM)23.38%

Revenue growth 3Y63.92%

Revenue growth 5Y94.61%

Sales Q2Q%82.18%

3.2 Future

Based on estimates for the next years, ARGX will show a very strong growth in Earnings Per Share. The EPS will grow by 69.22% on average per year.

ARGX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 25.14% yearly.

EPS Next Y346.1%

EPS Next 2Y185.47%

EPS Next 3Y113.42%

EPS Next 5Y69.22%

Revenue Next Year60.95%

Revenue Next 2Y45.7%

Revenue Next 3Y36.94%

Revenue Next 5Y25.14%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

ARGX is valuated quite expensively with a Price/Earnings ratio of 253.61.

Compared to the rest of the industry, the Price/Earnings ratio of ARGX indicates a somewhat cheap valuation: ARGX is cheaper than 76.39% of the companies listed in the same industry.

The average S&P500 Price/Earnings ratio is at 29.35. ARGX is valued rather expensively when compared to this.

A Price/Forward Earnings ratio of 56.79 indicates a quite expensive valuation of ARGX.

ARGX's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. ARGX is cheaper than 77.78% of the companies in the same industry.

When comparing the Price/Forward Earnings ratio of ARGX to the average of the S&P500 Index (22.10), we can say ARGX is valued expensively.

		Industry Rank	Sector Rank
PE	253.61
Fwd PE	56.79

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

ARGX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.

A more expensive valuation may be justified as ARGX's earnings are expected to grow with 113.42% in the coming years.

PEG (NY)0.73

PEG (5Y)N/A

EPS Next 2Y185.47%

EPS Next 3Y113.42%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for ARGX!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

ARGENX SE

EBR:ARGX (3/7/2025, 7:00:00 PM)

555.4

-22.8 (-3.94%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)02-27 2025-02-27/bmo

Earnings (Next)05-08 2025-05-08/bmo

Inst Owners39.35%

Inst Owner ChangeN/A

Ins Owners0.12%

Ins Owner ChangeN/A

Market Cap33.75B

Analysts78.4

Price Target658.04 (18.48%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)7929.96%

Min EPS beat(2)2.72%

Max EPS beat(2)15857.2%

EPS beat(4)3

Avg EPS beat(4)3994.6%

Min EPS beat(4)-26.77%

Max EPS beat(4)15857.2%

EPS beat(8)6

Avg EPS beat(8)2008.22%

EPS beat(12)9

Avg EPS beat(12)1348.21%

EPS beat(16)13

Avg EPS beat(16)1030.35%

Revenue beat(2)2

Avg Revenue beat(2)6.93%

Min Revenue beat(2)6.88%

Max Revenue beat(2)6.99%

Revenue beat(4)3

Avg Revenue beat(4)5.7%

Min Revenue beat(4)-0.25%

Max Revenue beat(4)9.17%

Revenue beat(8)7

Avg Revenue beat(8)7.67%

Revenue beat(12)11

Avg Revenue beat(12)27.71%

Revenue beat(16)14

Avg Revenue beat(16)43.74%

PT rev (1m)1.45%

PT rev (3m)11.84%

EPS NQ rev (1m)0%

EPS NQ rev (3m)22.2%

EPS NY rev (1m)3.88%

EPS NY rev (3m)64.44%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)8.25%

Revenue NY rev (1m)4.05%

Revenue NY rev (3m)21.21%

Valuation

		Industry Rank	Sector Rank
PE	253.61
Fwd PE	56.79
P/S	16.73
P/FCF	N/A
P/OCF	N/A
P/B	8.6
P/tB	8.89
EV/EBITDA	N/A

EPS(TTM)2.19

EY0.39%

EPS(NY)9.78

Fwd EY1.76%

FCF(TTM)N/A

FCFYN/A

OCF(TTM)N/A

OCFYN/A

SpS33.2

BVpS64.61

TBVpS62.46

PEG (NY)0.73

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	17.37%
ROE	19.54%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	38.03%
GM	89.62%
FCFM	N/A

ROA(3y)N/A

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-ScoreN/A

Asset Turnover0.46

Health

		Industry Rank	Sector Rank
Debt/Equity	0.01
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	8.53
Quick Ratio	7.88
Altman-Z	42.06

F-ScoreN/A

WACC7.37%

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)146.3%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%194.05%

EPS Next Y346.1%

EPS Next 2Y185.47%

EPS Next 3Y113.42%

EPS Next 5Y69.22%

Revenue 1Y (TTM)23.38%

Revenue growth 3Y63.92%

Revenue growth 5Y94.61%

Sales Q2Q%82.18%

Revenue Next Year60.95%

Revenue Next 2Y45.7%

Revenue Next 3Y36.94%

Revenue Next 5Y25.14%

EBIT growth 1Y97.67%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year670.86%

EBIT Next 3Y191.75%

EBIT Next 5Y106.28%

FCF growth 1YN/A

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1YN/A

OCF growth 3YN/A

OCF growth 5YN/A

ARGENX SE (ARGX.BR) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens